Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...

Following a price cut for its Repatha SureClick auto-injector in October, Amgen Inc. (AMGN) announced on Monday it is slashing the price of all Repatha devices by 60% to $5,850 per year. Repatha, one ...

The FDA approved Amgen’s AMGN new cholesterol-lowering medication, Repatha (evolocumab), making it the second PCSK9 inhibitor to gain approval in the U.S. this year. Repatha’s approval comes a month ...

Repatha works by blocking a specific enzyme in your liver to help your body remove cholesterol more effectively. It is not an immunosuppressant drug, so it doesn’t work by suppressing the immune ...

Amgen announced the submission of an application to the Food and Drug Administration (FDA) seeking approval of a single-injection option for the monthly administration of the 420mg dose of Repatha ...

The Food and Drug Administration (FDA) has approved Repatha (evolocumab; Amgen) for the treatment of high cholesterol in certain adults. The Food and Drug Administration (FDA) has approved Repatha ...

The US Food and Drug Administration (FDA) has approved Amgen's cholesterol-lowering medication, Repatha (evolocumab) injection, a human monoclonal antibody that inhibits proprotein convertase ...